The Health Research Authority (HSA) was established in 2011 with the core purpose of protecting and promoting the interests of patients and the public in health and social care research. For the past three years the HSA has focused on accelerating the research approval process, and ensuring the right level of diversity and inclusion in clinical trials. As the authority begins to develop its next three-year strategy, we asked Chief Executive Matt Westmore about progress to date, and what the UK needs to do to maintain its competitive position as a research powerhouse.
Our discussion covers the significant advances in health research during the COVID-19 pandemic, the importance of public trust in the research process, and how the National Health Service gives the UK a competitive advantage in attracting research projects from around the world.
Listen to the conversation on the latest episode of The Purposeful Strategist.
Matt Westmore